Approximately 1 in 10 people with COVID-19 continue to experience symptoms and impaired quality of life beyond 12 weeks, which is known as Long COVID. The team were funded £2.2 million to, at pace, improve the international understanding of this new condition.
Powered by DExtER, the team were able to become the first researchers globally to identify the full breadth of the symptom burden associated with Long COVID (Published in Nature Medicine). This included identifying less well-known side effects such as amnesia to look out for, as well as spot inequalities in the groups who presented with Long COVID, as we noticed those from poorer backgrounds, smokers and those overweight experienced a higher disease burden. Identification of the symptom burden is now allowing clinicians and clinical guide developers to improve their assessment of patients experiencing the long term effects from COVID-19.